Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.49 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6908846 | 0.85 | TP53 (0.54) | ALDH1A1GLATSHRTP53OPRM1 | |
| SCHEMBL30268640 | 0.85 | ALDH1A1 (0.52) | ALDH1A1GLATSHRTP53OPRM1 | |
| SCHEMBL9716650 | 0.85 | TP53 (0.74) | ALDH1A1GLATSHRTP53LTB4R2 | |
| SCHEMBL6470863 | 0.85 | ESR1 (0.41) | ALDH1A1GLATSHRTP53LTB4R2 | |
| SCHEMBL2030599 | 0.84 | ALDH1A1 (0.70) | ALDH1A1GLATSHRTP53OPRM1 | |
| SCHEMBL28388854 | 0.84 | ALDH1A1 (0.50) | ALDH1A1GLATSHRTP53OPRM1 | |
| SCHEMBL31480004 | 0.84 | ALDH1A1 (0.55) | ALDH1A1GLATSHRTP53OPRM1 | |
| SCHEMBL6907477 | 0.83 | ALDH1A1 (0.49) | ALDH1A1GLATSHRTP53CYP3A4 | |
| Dl-Phenylalanine SCHEMBL20898600 | 0.83 | SLC7A5 (0.58) | ALDH1A1OPRM1SIGMAR1SMN1; SMN2MEN1 | |
| SCHEMBL6901552 | 0.82 | SMN1; SMN2 (0.60) | ALDH1A1GLATSHRTP53OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12050228-B2 | Automated sample quality assessment | METABOLON, INC. (US) | 2024-07-30 | — | — | US | claimed |
| US-20230233620-A1 | HIGH-COMPLEXITY SYNTHETIC GUT BACTERIAL COMMUNITIES | Kanvas Biosciences, Inc. | 2023-07-27 | — | — | US | claimed |
| EP-4152959-A1 | HIGH-COMPLEXITY SYNTHETIC GUT BACTERIAL COMMUNITIES | Chan Zuckerberg Biohub, Inc. (US) | 2023-03-29 | — | — | EP | claimed |
| US-20220233611-A1 | COMPOSITIONS AND METHODS FOR PROMOTING HEALTHY NEURAL DEVELOPMENT IN AN UNBORN BABY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-07-28 | — | — | US | claimed |
| EP-3965820-A1 | COMPOSITIONS AND METHODS FOR PROMOTING HEALTHY NEURAL DEVELOPMENT IN AN UNBORN BABY | The Regents of the University of California (US) | 2022-03-16 | — | — | EP | claimed |
| US-20220050090-A1 | MASS SPECTROMETRY ASSAY METHOD FOR DETECTION AND QUANTITATION OF MICROBIOTA RELATED METABOLITES | METABOLON, INC. | 2022-02-17 | — | — | US | claimed |
| WO-2021237162-A1 | HIGH-COMPLEXITY SYNTHETIC GUT BACTERIAL COMMUNITIES | CHAN ZUCKERBERG BIOHUB, INC. (US) | 2021-11-25 | — | — | WO | claimed |
| US-20210353611-A1 | METHODS OF TREATING AMYOTROPHIC LATERAL SCLEROSIS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2021-11-18 | — | — | US | claimed |
| EP-3852759-A2 | METHODS OF TREATING AMYOTROPHIC LATERAL SCLEROSIS | Yeda Research and Development Co. Ltd (IL) | 2021-07-28 | — | — | EP | claimed |
| EP-3850359-A1 | MASS SPECTROMETRY ASSAY METHOD FOR DETECTION AND QUANTITATION OF MICROBIOTA-RELATED METABOLITES | Metabolon Inc. (US) | 2021-07-21 | — | — | EP | claimed |
| WO-2015157407-A1 | SMALL MOLECULE BIOCHEMICAL PROFILING OF INDIVIDUAL SUBJECTS FOR DISEASE DIAGNOSIS AND HEALTH ASSESSMENT | METABOLON, INC. (US) | 2015-10-15 | — | — | WO | claimed |
| US-20150065366-A1 | Biomarkers for Bladder Cancer and Methods Using the Same | METABOLON, INC. | 2015-03-05 | — | — | US | claimed |
| EP-2776832-A1 | BIOMARKERS FOR BLADDER CANCER AND METHODS USING THE SAME | Metabolon, Inc. (US) | 2014-09-17 | — | — | EP | claimed |
| WO-2013070839-A1 | BIOMARKERS FOR BLADDER CANCER AND METHODS USING THE SAME | METABOLON, INC. (US) | 2013-05-16 | — | — | WO | claimed |
| US-20050171194-A1 | Enlargement of mucocutaneous or cutaneous organs and sites with topical compositions | YU RUEY J (US) | 2005-08-04 | — | — | US | claimed |
| WO-2005055947-A2 | ENLARGEMENT OF MUCOCUTANEOUS OR CUTANEOUS ORGANS AND SITES WITH TOPICAL COMPOSITIONS | YU RUEY J (US) | 2005-06-23 | — | — | WO | claimed |
| US-6824786-B2 | TOPICAL APPLYING COSMETIC | YU RUEY J (US) | 2004-11-30 | — | — | US | claimed |
| EP-1455734-A1 | COMPOSITIONS COMPRISING PHENYL-GLYCINE DERIVATIVES | Yu, Ruey J., Dr. (US) | 2004-09-15 | — | — | EP | claimed |
| US-20030108496-A1 | Compositions comprising phenyl-glycine derivatives | YU RUEY J (US) | 2003-06-12 | — | — | US | claimed |
| WO-2003045338-A1 | COMPOSITIONS COMPRISING PHENYL-GLYCINE DERIVATIVES | YU RUEY J (US) | 2003-06-05 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030108496-A1 | Compositions comprising phenyl-glycine derivatives | GRHPR, ARL1, SUCLG1 | ALDH1A1 1110/4885GLA 61/4885TSHR 3740/4885 |
| US-20210353611-A1 | METHODS OF TREATING AMYOTROPHIC LATERAL SCLEROSIS | SMN1; SMN2, SOD1, OAT | ALDH1A1 665/4885GLA 348/4885TSHR 4408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.